Injecties onnodig: immuniteit tegen COVID-19 bestaat al.
Het is dus ook geen uniek nieuw virus, zoals de WHO stelde
Mike Yeadon (ex-vice president Pfizer) stelde: “The reality was clear as soon as the sequence of the “new” virus was published. Sure, it’s a new sequence, but there’s no such thing as an ancestorless virus. Turns out there are multiple, common cold causing coronaviruses & also previous nastier CoVs. As a result, 20-50% of naive subjects had prior immunity as evidenced by T-cell responsiveness to epitopes from the new virus.”
De volgende studies tonen dit aan. Ze zijn geordend naar datum van publicatie.
“This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses.”
“Several studies have reported that some people who have not been exposed to SARS-CoV-2 have preexisting reactivity to SARS-CoV-2 sequences. (…) Mateus et al. found that the preexisting reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of preexisting immune memory in COVID-19 disease severity.”
“The anti-S2 antibodies from SARS-CoV-2–uninfected patients showed specific neutralizing activity against both SARS-CoV-2 and SARS-CoV-2 S pseudotypes. A much higher percentage of SARS-CoV-2–uninfected children and adolescents were positive for these antibodies compared with adults.”
Datum: 12-3-2021 (geaccepteerd)
Deze studie komt het hoogste uit: meer dan 90% van de niet-geinfecteerde volwassenen.
“(…) we determined that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2. (…) We conclude that most adults display preexisting antibody cross-reactivity against SARS-CoV-2, which further supports investigation of how this may impact the clinical severity of COVID-19 or SARS-CoV-2 vaccine responses.”
Natuurlijke immuniteit werkt beter dan die via vaccins. Onderzoek in Israel, Delta-variant.